🪙SEC Notice on Bitwise Dogecoin ETF Trading Proposal
The SEC issued a notice regarding the proposed rule change by NYSE Arca to list and trade shares of the Bitwise Dogecoin ETF. This document solicits public comments and discusses the operations, governance, and implications of the Trust, including the mechanisms for trading and valuation.
Learn More🐟Public Meeting Notice from Pacific Fishery Management Council
The Pacific Fishery Management Council's (Pacific Council) Highly Migratory Species Management Team (HMSMT) will hold an online meeting that is open to the public.
Learn More🏗️Certification of Tariff Processing Systems on Steel and Aluminum
On February 10, 2025, the President issued Proclamations 10895 "Adjusting Imports of Aluminum into The United States" (Aluminum Proclamation), and 10896 "Adjusting Imports of Steel into the United States" (Steel Proclamation), imposing specified rates of duty on imports of aluminum and steel, respectively (collectively, the Proclamations). The Proclamations also required the Secretary of Commerce to certify that adequate systems are in place to fully, efficiently, and expediently process and collect tariff revenue for covered articles. This notice certifies that adequate systems are in place to fully, efficiently, and expediently process and collect tariff revenue for covered articles for both steel and aluminum.
Learn More💰NYSE American Proposes Changes to Options Fee Schedule
The NYSE American LLC has filed a proposed rule change to increase manual transaction fees for specialists and e-specialists and to remove outdated language from the Options Fee Schedule. This change is aimed at modernizing the fee structure, with immediate effectiveness designated as of March 2025. The proposal invites comments from interested parties regarding its consistency with existing regulations.
Learn More💊FDA Withdraws Approval of Abbreviated New Drug Applications
The Food and Drug Administration (FDA or Agency) is withdrawing approval of four abbreviated new drug applications (ANDAs) from multiple applicants. The applicants notified the Agency in writing that the drug products were no longer marketed and requested that the approval of the applications be withdrawn.
Learn More💰NYSE American Proposes Rule Change to Increase Port Fees
The Securities and Exchange Commission has published a notice regarding NYSE American LLC's proposed rule change to increase port fees and remove the open outcry port fee discount. This change is effective immediately and aims to adjust the Fee Schedule, with an invitation for public comments.
Learn More🎣South Atlantic Fishery Management Council Meeting Notice
The South Atlantic Fishery Management Council (Council) will host a meeting of the Mackerel Cobia Advisory Panel on March 31 and April 1, 2025.
Learn More🌊Notice of Environmental Assessment for Hydro Project by DOE
The Department of Energy has released an Environmental Assessment concerning the Santa Felicia Hydroelectric Project in Ventura County, California. The assessment evaluates potential environmental impacts of proposed safety improvements at the Santa Felicia Dam, concluding that the actions would not significantly affect the human environment. Public comments are welcomed until April 7, 2025.
Learn More🏦FDIC Withdraws Proposed Banking Regulations Affecting Corporations
The Federal Deposit Insurance Corporation (FDIC) is withdrawing notices of proposed rulemaking relating to brokered deposit restrictions, corporate governance and risk management, and the Change in Bank Control Act. If the FDIC decides to pursue future regulatory action in any of these areas, it will issue a new proposed rule.
Learn More⚖️FDA Denies Hearing and Issues Permanent Debarment for Garmendia
The Food and Drug Administration (FDA or Agency) is denying a request for a hearing submitted by Bernardo Garmendia, also known as Bernardo Germendia, (Garmendia) and is issuing an order under the Federal Food, Drug, and Cosmetic Act (FD&C Act) permanently debarring Garmendia from providing services in any capacity to a person that has an approved or pending drug product application. FDA bases this order on a finding that Garmendia was convicted of a felony under Federal law for conduct relating to the development or approval, including the process for development or approval, of any drug product under the FD&C Act. FDA provided notice to Garmendia of the proposed debarment and an opportunity to request a hearing within the timeframe prescribed by regulation. Garmendia submitted a request for hearing but failed to file with the Agency information and analyses sufficient to create a basis for a hearing.
Learn More